Alzheimer Research Forum Live Discussion: Making a BioMark on Alzheimer Disease

John Trojanowski: Okay, Tom. Briefly, we will focus here on chemical analyte biomarkers in various bodily fluids such as cerebrospinal fluid (CSF), urine, blood, etc., and while genetics may come up, too, we will save imaging biomarkers for another time. Concerning apolipoprotein E (ApoE): It does seem to be critical to consider this for cohort assignment as demonstrated in the recent NEJM paper from R. Peterson [1] on mild cognitive impairment (MCI), and we will do this as well in the Alzheimer Disease Neuroimaging Initiative (ADNI) study.